BRAF and metastatic melanoma: Both, MEK inhibitors and PPARγ agonists are used in a novel function compared to the common ways of application, namely for efficacious targeted control of BRAF mutated metastatic melanoma in combination with BRAF inhibitors or for overcoming insulin resistance, respectively.